SEC Tracker
Get the app

Possible new DSGN shares

DSGNDilution

Known so far: no new shares from the prospectus covers read · shelf not limited by the baby-shelf rule · not yet read: warrants, converts.

Shelf room

  • Room today not capped by the baby-shelf rule ($114M float, Jun 30, 2025)
How this is worked out

Shelf room on the S-3 of May 7, 2025: not limited by the baby-shelf rule, because the $114M public float stated as of Jun 30, 2025 is $75M or more. Sources: S-3 May 7, 2025, effective May 16, 2025 · public float, as of Jun 30, 2025.

What could become new Design Therapeutics (DSGN) shares: options and RSUs and an ATM program, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

DSGN dilution ladder

Every source of new shares on record, from the filings that created it.

64M outstanding; up to 101.2M fully diluted, +58%

  1. Outstandingas of Oct 30, 2026 (10-Q filed Nov 4) · share count on the cover page
    64M
  2. At-the-market program$200.0M program424B5 Nov 4, 2026 · At-the-market prospectus supplementat $10.34, stated in the filing on Nov 3
    +19.3M
  3. Options and RSUs17.8M options10-Q Nov 4, 2026 · equity note
    +17.8M

Not stated in the filings we read: warrants, convertible notes.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Financing terms to know

None found in filings since Nov 4, 2026.

Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.

Shares outstanding

64.0M

Mar 2025 to Oct 2026: from 56.8M to 64.0M.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.

Data on this page was fetched . The filing on SEC.gov is the record.